vs

Side-by-side financial comparison of Fifth District Bancorp, Inc. (FDSB) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $3.6M, roughly 1.8× Fifth District Bancorp, Inc.). Fifth District Bancorp, Inc. runs the higher net margin — 14.9% vs 12.9%, a 2.0% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 19.9%). Fifth District Bancorp, Inc. produced more free cash flow last quarter ($942.0K vs $-5.3M).

Fifth Third Bancorp is a bank holding company headquartered in Cincinnati, Ohio. It is the parent company of Fifth Third Bank, which operates 1,087 branches and 2,400 automated teller machines, across 12 states: Ohio, Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, North Carolina, South Carolina, Tennessee, and West Virginia. It is on the list of largest banks in the United States and is ranked 321st on the Fortune 500. The name "Fifth Third" is derived from the names of the...

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

FDSB vs LCTX — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.8× larger
LCTX
$6.6M
$3.6M
FDSB
Growing faster (revenue YoY)
LCTX
LCTX
+110.5% gap
LCTX
130.4%
19.9%
FDSB
Higher net margin
FDSB
FDSB
2.0% more per $
FDSB
14.9%
12.9%
LCTX
More free cash flow
FDSB
FDSB
$6.2M more FCF
FDSB
$942.0K
$-5.3M
LCTX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FDSB
FDSB
LCTX
LCTX
Revenue
$3.6M
$6.6M
Net Profit
$541.0K
$851.0K
Gross Margin
Operating Margin
17.0%
-99.1%
Net Margin
14.9%
12.9%
Revenue YoY
19.9%
130.4%
Net Profit YoY
240.3%
126.0%
EPS (diluted)
$0.10
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDSB
FDSB
LCTX
LCTX
Q4 25
$3.6M
$6.6M
Q3 25
$3.6M
$3.7M
Q2 25
$6.9M
$2.8M
Q1 25
$3.2M
$1.5M
Q4 24
$2.9M
Q3 24
$3.1M
$3.8M
Q2 24
$2.7M
$1.4M
Q1 24
$1.2M
$1.4M
Net Profit
FDSB
FDSB
LCTX
LCTX
Q4 25
$541.0K
$851.0K
Q3 25
$343.0K
$-29.8M
Q2 25
$3.1M
$-30.5M
Q1 25
$78.0K
$-4.1M
Q4 24
$-3.3M
Q3 24
$-788.0K
$-3.0M
Q2 24
$683.0K
$-5.8M
Q1 24
$-1.1M
$-6.5M
Gross Margin
FDSB
FDSB
LCTX
LCTX
Q4 25
Q3 25
Q2 25
Q1 25
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Q1 24
93.2%
Operating Margin
FDSB
FDSB
LCTX
LCTX
Q4 25
17.0%
-99.1%
Q3 25
12.1%
-102.9%
Q2 25
44.2%
-715.4%
Q1 25
3.1%
-433.1%
Q4 24
-178.2%
Q3 24
-31.8%
-101.6%
Q2 24
32.3%
-416.7%
Q1 24
-124.5%
-461.3%
Net Margin
FDSB
FDSB
LCTX
LCTX
Q4 25
14.9%
12.9%
Q3 25
9.6%
-809.0%
Q2 25
45.5%
-1101.8%
Q1 25
2.4%
-275.6%
Q4 24
-114.1%
Q3 24
-25.1%
-80.3%
Q2 24
25.5%
-409.1%
Q1 24
-98.3%
-453.0%
EPS (diluted)
FDSB
FDSB
LCTX
LCTX
Q4 25
$0.10
$0.00
Q3 25
$0.07
$-0.13
Q2 25
$0.61
$-0.13
Q1 25
$0.02
$-0.02
Q4 24
$0.00
Q3 24
$-0.15
$-0.02
Q2 24
$-0.03
Q1 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDSB
FDSB
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$33.9M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$129.8M
$44.5M
Total Assets
$534.4M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDSB
FDSB
LCTX
LCTX
Q4 25
$33.9M
$55.8M
Q3 25
$34.4M
$40.5M
Q2 25
$27.7M
$42.3M
Q1 25
$30.1M
$47.9M
Q4 24
$47.8M
Q3 24
$34.1M
$32.7M
Q2 24
$46.2M
$38.5M
Q1 24
$36.6M
$43.6M
Stockholders' Equity
FDSB
FDSB
LCTX
LCTX
Q4 25
$129.8M
$44.5M
Q3 25
$131.3M
$22.0M
Q2 25
$130.9M
$48.4M
Q1 25
$127.3M
$79.0M
Q4 24
$78.4M
Q3 24
$127.9M
$66.2M
Q2 24
$78.0M
$68.3M
Q1 24
$77.0M
$72.4M
Total Assets
FDSB
FDSB
LCTX
LCTX
Q4 25
$534.4M
$112.6M
Q3 25
$539.5M
$89.6M
Q2 25
$539.8M
$90.8M
Q1 25
$531.1M
$111.8M
Q4 24
$113.2M
Q3 24
$523.8M
$96.6M
Q2 24
$516.0M
$102.8M
Q1 24
$485.7M
$108.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDSB
FDSB
LCTX
LCTX
Operating Cash FlowLast quarter
$1.3M
$-4.9M
Free Cash FlowOCF − Capex
$942.0K
$-5.3M
FCF MarginFCF / Revenue
25.9%
-79.9%
Capex IntensityCapex / Revenue
10.6%
6.0%
Cash ConversionOCF / Net Profit
2.45×
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$2.0M
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDSB
FDSB
LCTX
LCTX
Q4 25
$1.3M
$-4.9M
Q3 25
$117.0K
$-3.6M
Q2 25
$430.0K
$-5.5M
Q1 25
$823.0K
$-4.9M
Q4 24
$-6.3M
Q3 24
$734.0K
$-5.8M
Q2 24
$-385.0K
$-5.2M
Q1 24
$-770.0K
$-5.8M
Free Cash Flow
FDSB
FDSB
LCTX
LCTX
Q4 25
$942.0K
$-5.3M
Q3 25
$54.0K
$-3.6M
Q2 25
$249.0K
$-5.6M
Q1 25
$765.0K
$-5.0M
Q4 24
$-6.7M
Q3 24
$710.0K
$-5.9M
Q2 24
$-501.0K
$-5.2M
Q1 24
$-1.1M
$-5.8M
FCF Margin
FDSB
FDSB
LCTX
LCTX
Q4 25
25.9%
-79.9%
Q3 25
1.5%
-98.6%
Q2 25
3.6%
-200.8%
Q1 25
23.9%
-331.8%
Q4 24
-234.0%
Q3 24
22.6%
-156.1%
Q2 24
-18.7%
-371.2%
Q1 24
-96.8%
-403.1%
Capex Intensity
FDSB
FDSB
LCTX
LCTX
Q4 25
10.6%
6.0%
Q3 25
1.8%
0.3%
Q2 25
2.6%
0.5%
Q1 25
1.8%
6.5%
Q4 24
12.7%
Q3 24
0.8%
3.0%
Q2 24
4.3%
3.6%
Q1 24
29.9%
2.6%
Cash Conversion
FDSB
FDSB
LCTX
LCTX
Q4 25
2.45×
-5.73×
Q3 25
0.34×
Q2 25
0.14×
Q1 25
10.55×
Q4 24
Q3 24
Q2 24
-0.56×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDSB
FDSB

Segment breakdown not available.

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons